6-acetyl-8-cyclopentyl-5-methyl-2-((5-(4-nitrosopiperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one

Catalog No. :
ACHKUN033
CAS No. :
2955712-44-2
Molecular Formula :
C24H28N8O3
Molecular Weight :
476.54

IUPAC Name:6-acetyl-8-cyclopentyl-5-methyl-2-((5-(4-nitrosopiperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one

6-acetyl-8-cyclopentyl-5-methyl-2-((5-(4-nitrosopiperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-acetyl-8-cyclopentyl-5-methyl-2-((5-(4-nitrosopiperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
IUPAC Name6-acetyl-8-cyclopentyl-5-methyl-2-((5-(4-nitrosopiperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one
Molecular FormulaC24H28N8O3
Molecular Weight476.54
SMILESCC(C1=CN=C(NC2=CC=C(N3CCN(N=O)CC3)C=N2)N=C1N4C5CCCC5)=C(C(C)=O)C4=O
InChI KeyBXUXPPSEBPSYOT-UHFFFAOYSA-N
SynonymPalbociclib Impurity 31;6-acetyl-8-cyclopentyl-5-methyl-2-((5-(4-nitrosopiperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d]pyrimidin-7(8H)-one;N-Nitroso Palbociclib 1
CAS No.2955712-44-2

Synthetic Route by SureRoute

1. ACHKUN033 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCTJQ587 route compound structure diagram
    ACCTJQ587571190-30-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHKUN033 route product structure diagram
    ACHKUN0332955712-44-2
Inquiry

2. ACHKUN033 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACCTJQ587 route compound structure diagram
    ACCTJQ587571190-30-2 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACHKUN033 route product structure diagram
    ACHKUN0332955712-44-2
Inquiry

Comments (0)